In VivoPIB PET Amyloid Imaging: Normals, MCI & Dementia

描述(由申请人提供)：使用新型正电子发射断层扫描(PET)示踪剂匹兹堡化合物B(PIB)的第一项概念验证研究表明，PIB-PET成像检测到活着的AD受试者大脑中淀粉样蛋白沉积的模式与尸检研究预测的类似。这项建议的总体目标是定义AD早期阶段的淀粉样蛋白沉积，并通过检测PIB滞留和其他代谢和结构标记物，帮助表征PIB作为淀粉样蛋白沉积的替代标记物。这些研究提出了3个主要问题：1)在正常老年人、轻度认知障碍(MCI)和轻、中、重度阿尔茨海默病(AD)患者中，PIB的沉积是否可被检测到，并与整体认知的严重程度或涉及大脑特定区域的认知功能定量相关？2)在一项每年进行PIB-PET和认知评估的纵向研究中，这些受试者是否会显示PIB滞留(β淀粉样蛋白的量)增加？3)在帕金森病(PD)的临床范围内，PIB滞留的发生率是多少？帕金森病伴痴呆(PDD)和路易体痴呆(DLB)；在这些患者中观察到的临床痴呆症状中有多少淀粉样蛋白沉积？我们还将进行氟脱氧葡萄糖正电子发射计算机断层扫描(FDG-PET)和磁共振成像，以关联代谢和容量数据、认知和PIB沉积。为了实现这些目标，我们建立了一个行政核心来监督和协调项目、预算和数据传输；一个临床核心来识别和评估来自匹兹堡大学ADRC和匹兹堡退伍军人健康系统神经科和运动障碍诊所的受试者；以及一个由UPMC PET中心和放射科研究人员组成的成像、方法和统计(IMS)核心。多年来，研究人员在ADRC和帕金森中心的研究和护理方面密切合作，这一事实确保了有效的合作。

DESCRIPTION (provided by applicant): The first proof-of-concept studies using the new positron emission tomography (PET) tracer, Pittsburgh compound-B (PIB), showed that PIB-PET imaging detected amyloid deposition in the brains of living AD subjects in a pattern similar to that predicted by autopsy studies. The overall objective of this proposal is to define amyloid deposition in early phases of AD and aid in the characterization of PIB as a surrogate marker of amyloid deposition by examining PIB retention and other metabolic and structural makers. The studies ask 3 major questions: 1) in normal elderly subjects, subjects with mild cognitive impairment (MCI), and mild, moderate, and severe Alzheimer's disease (AD), will deposition of PIB be detectable and correlate quantitatively with the level of severity of overall cognition, or cognitive functions referable to specific areas of the brain? 2) Will these subjects show increases in PIB retention (amount of beta amyloid) in a longitudinal study in which PIB-PET and cognitive assessments are performed annually for up to three years? 3) What is the prevalence of PIB retention across the clinical spectrum of Parkinson's Disease (PD), PD with dementia (PDD) and Dementia with Lewy Bodies (DLB); how much amyloid deposition underlies clinical dementia symptoms observed in these patients? We will also perform fluorodeoxyglucose PET (FDG-PET) and MRI to correlate metabolic and volumetric data, cognition, and PIB deposition. To accomplish these objectives we have established an Administrative Core to oversee & coordinate the projects, budgets, and data transfers; a Clinical Core to identify and assess subjects from the University of Pittsburgh ADRC and the Movement Disorders Clinics in the Department of Neurology and the Pittsburgh VA Health System and an Imaging, Methodology and Statistics (IMS) Core comprised of researchers from the UPMC PET Center and the Department of Radiology. Effective collaborations are assured by the fact that the investigators have worked together closely in research & care in the ADRC and the Parkinson's Center for many years.